Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933229 | 0.86 | GAA (0.47) | MAOBGAAKDM4EKMT2AHTT | |
| SCHEMBL26082900 | 0.86 | MAOB (0.36) | MAOBGAAKDM4EKMT2AHTT | |
| SCHEMBL2594876 | 0.84 | MAOB (0.49) | MAOBCA1CA2CA9GAA | |
| SCHEMBL2302250 | 0.82 | MAOB (0.48) | MAOBCA1CA2CA9GAA | |
| SCHEMBL1463813 | 0.82 | MAOB (0.48) | MAOBCA1CA2CA9GAA | |
| SCHEMBL20313798 | 0.81 | MAOB (0.34) | MAOBGAAKDM4EKMT2AHTT | |
| SCHEMBL2594522 | 0.81 | MAOB (0.47) | MAOBCA1CA2CA9GAA | |
| SCHEMBL2025665 | 0.79 | MAOB (0.33) | MAOB | |
| SCHEMBL30071045 | 0.79 | ALDH1A1 (0.50) | MAOBCA1CA2CA9GAA | |
| SCHEMBL16161453 | 0.79 | MAOB (0.43) | MAOBCA1CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119919837-A | IASL-YOLO-based unmanned aerial vehicle small target detection method and device | 昆明理工大学 | 2025-05-02 | — | — | CN | claimed |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2025-02-06 | — | — | US | claimed |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-12-19 | — | — | US | claimed |
| WO-2023229323-A1 | METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE | 일동제약(주) | 2023-11-30 | — | — | WO | claimed |
| US-20230203091-A1 | GLYCOCONJUGATION PROCESS | PFIZER (US) | 2023-06-29 | — | — | US | claimed |
| CN-115794259-B | Method for generating device tree through ACPI | 麒麟软件有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-115686889-B | Method for using Ivshmem by Jailhouse based on ACPI | 麒麟软件有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115543545-B | Method for realizing equipment isolation by using ACPI (application specific protocol) by Jailhouse | 麒麟软件有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115794259-A | Method for generating device tree through ACPI | 麒麟软件有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115686889-A | Method for using Ivshmem by Jailhouse based on ACPI | 麒麟软件有限公司 | 2023-02-03 | — | — | CN | claimed |
| EP-2755989-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | Stora Enso Oyj (FI) | 2014-07-23 | — | — | EP | claimed |
| WO-2014097099-A2 | GLYCOCONJUGATION PROCESS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | claimed |
| US-20130296599-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | VTV THERAPEUTICS LLC | 2013-11-07 | — | — | US | claimed |
| WO-2013038316-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | claimed |
| WO-2012096824-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | TRANSTECH PHARMA, INC. (US) | 2012-07-19 | — | — | WO | claimed |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | MITOS PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | claimed |
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | MITOS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | claimed |
| WO-2008104683-A1 | ELECTRODE CONTAINING AT LEAST ONE NITROXIDE AND CARBON NANOTUBES | ARKEMA FRANCE (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | TXNRD2, TET1, TXNRD3 | MAOB 1998/4885CA1 3929/4885CA2 2799/4885 |
| US-20130296599-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | HPD, GRHPR, AGXT | MAOB 694/4885CA1 3512/4885CA2 2005/4885 |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | MAOB 501/4885CA1 885/4885CA2 1675/4885 |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | GPX1, GPX4, SOD1 | MAOB 272/4885CA1 826/4885CA2 2082/4885 |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | MAOB 2138/4885CA1 2244/4885CA2 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.